The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...

RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...

A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new ...

Please provide your email address to receive an email when new articles are posted on . Gaps in access remain, though, as almost half of patients did not receive next-generation sequencing. “These ...

HER2 mutations involve genetic alterations, while HER2 expression refers to protein overexpression, both impacting NSCLC treatment strategies. Fam-trastuzumab deruxtecan-nxki and ado-trastuzumab ...

With the evolving landscape of metastatic non-small cell lung cancer (NSCLC) treatment, standardized guidelines are invaluable in patient management. Current treatment strategies depend on the ...

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted ...

The American Society for Radiation Oncology (ASTRO) has issued new guidelines on the appropriate use of stereotactic radiation (SBRT) in early-stage non-small cell lung cancer (NSCLC), now the leading ...

EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic ...

Sample management algorithm for average-risk patients. A. Resection suggested over stereotactic body radiotherapy or ablative techniques. B. Resection by a board-certified thoracic surgeon suggested.

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest ...